S&P 500 Industrials Sector SEC Filings — February 25, 2026

26-02-2026

Autodesk, Inc. filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information. No positive or negative performance details, period-over-period comparisons, or forward-looking statements are mentioned.

26-02-2026

Hormel Foods Corp /DE/ filed an 8-K on February 26, 2026 (AccNo: 0000048465-26-000018), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. Sector is not specified.

• ·Filing size: 541 KB
• ·Event Type: Financial Results
• ·Source: us_sec

26-02-2026

Carriage Services Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no quantitative financial metrics available.

26-02-2026

Wolverine World Wide Inc. (/DE/) filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011956, Size: 690 KB), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item, voluntary earnings-related filing typical for US public companies. No specific quantitative financial metrics, period-over-period comparisons, guidance, or other numerical data are provided in the filing description.

26-02-2026

Collegium Pharmaceutical, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011990), under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing announces financial results, but no specific revenue, earnings, guidance, or other quantitative metrics are disclosed. No positive or negative performance indicators, period-over-period comparisons, or balance sheet details are provided.

26-02-2026

Shenandoah Telecommunications Co/VA/ filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or period-over-period comparisons were disclosed in the filing summary. This is a standard earnings-related disclosure with all quantitative financial metrics NOT_DISCLOSED.

26-02-2026

Biocryst Pharmaceuticals Inc. filed a Form 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing related to financial results with AccNo 0001171843-26-001119 and file size 435 KB. No specific revenue, earnings, balance sheet details, guidance, or quantitative metrics are disclosed in the provided filing information.

26-02-2026

First Advantage Corp filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073071), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No revenue, earnings, margins, guidance, period-over-period changes, or other quantitative financial metrics were explicitly stated in the filing description. This is a standard voluntary disclosure of financial results without detailed data provided.

• ·File size: 1 MB

26-02-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. Critical event content is missing, limiting assessment of impact.

26-02-2026

Aurinia Pharmaceuticals Inc. filed an 8-K on 2026-02-26 (AccNo: 0001600620-26-000015, Size: 357 KB) under Item 2.02 disclosing results of operations and financial condition. No quantitative financial metrics, revenue, earnings, guidance, or period-over-period comparisons are mentioned in the provided filing information. Sector is not specified.

26-02-2026

Ducommun Inc./DE/ filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011949, Size: 754 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on financial results with no specific quantitative metrics, period-over-period changes, positive or negative performance indicators disclosed in the provided information. No revenue, earnings, guidance, or balance sheet details are mentioned.

26-02-2026

Ligand Pharmaceuticals Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0000886163-26-000003), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on financial results disclosure. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information.

26-02-2026

Hilton Grand Vacations Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are mentioned in the provided filing details. All quantitative financial metrics are NOT_DISCLOSED.

26-02-2026

Phathom Pharmaceuticals, Inc. filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits provided under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or quantitative metrics are disclosed in the filing summary. This is a standard voluntary disclosure for financial results, likely related to quarterly or annual earnings.

26-02-2026

Niagen Bioscience, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001386570-26-000003, Size: 162 KB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the core events, transactions, financial impacts, or exhibits provided in the summary. No quantitative metrics, positive or negative changes, or period-over-period comparisons are disclosed.

26-02-2026

Butterfly Network, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, period-over-period changes, or other quantitative metrics are disclosed in the provided filing information.

26-02-2026

Hagerty, Inc. filed a Form 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, Item 7.01 for Regulation FD disclosure, and Item 9.01 for financial statements and exhibits. This is a multi-item filing announcing financial results, but specific revenue, earnings, or other quantitative metrics are NOT_DISCLOSED. No period-over-period comparisons, guidance, or balance sheet effects are provided in the filing description.

26-02-2026

Kairos Pharma, LTD. filed a Form 8-K on February 26, 2026 (AccNo: 0001493152-26-008116), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the financial statements and exhibits are disclosed in the provided filing summary. This appears to be a multi-item, likely voluntary disclosure with no quantified financial or operational impacts mentioned.

26-02-2026

Viridian Therapeutics, Inc. filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet metrics, period-over-period changes, or guidance were disclosed in the provided filing information. This appears to be an earnings-related disclosure, but detailed financial data is NOT_DISCLOSED.

26-02-2026

Payoneer Global Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, period-over-period changes, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with no directional financial data available.

26-02-2026

Rhythm Pharmaceuticals, Inc. filed an 8-K on 2026-02-26 reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a multi-item filing focused on financial results disclosure.

26-02-2026

Crescent Biopharma, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011988, Size: 319 KB), disclosing results of operations and financial condition under Item 2.02 along with financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were provided in the filing summary. This represents a standard voluntary earnings-related disclosure with no directional financial metrics disclosed.

26-02-2026

Heron Therapeutics, Inc. filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits provided under Item 9.01. This is a multi-item filing focused on financial results disclosure. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative data were detailed in the filing summary provided.

26-02-2026

ACI Worldwide, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details on the officer involved, nature of the change, financial metrics, or any quantitative data are disclosed in the provided filing information. No positive, negative, or flat performance metrics are mentioned.

26-02-2026

Delcath Systems, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition as part of its financial results announcement. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were mentioned in the provided filing information. All quantitative metrics and further details are NOT_DISCLOSED.

26-02-2026

Golden Matrix Group, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001477932-26-001050, Size: 185 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, financial metrics, or quantitative data disclosed in the provided summary. No positive, negative, or flat performance metrics are mentioned.

26-02-2026

CACI International Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the financial statements and exhibits are disclosed in the provided filing summary. This appears to be a multi-item informational filing with no quantified metrics or directional impacts mentioned.

26-02-2026

Edgewise Therapeutics, Inc. filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period changes, guidance, or other quantitative financial data are mentioned in the filing description. This appears to be a standard voluntary quarterly financial results disclosure.

26-02-2026

Sunoco LP filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073531), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely disclosing financial results, but no specific revenue, earnings, or other quantitative metrics are mentioned. No positive or negative performance indicators, comparisons, or guidance changes are provided in the filing details.

26-02-2026

Hertz Global Holdings, Inc. filed an 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative financial data are explicitly stated in the provided filing details. This appears to be a standard earnings-related disclosure without detailed metrics available.

26-02-2026

U S PHYSICAL THERAPY INC /NV filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). Specific details on the officer, position, reason for change, or any impacts are NOT_DISCLOSED.

• ·Filing Accession Number: 0001140361-26-006882
• ·File size: 1 MB
• ·Sector: NOT_DISCLOSED

26-02-2026

Bank of New York Mellon Corp filed an 8-K on February 26, 2026, reporting solely under Item 8.01 Other Events. No details on the specific event, financial impacts, transactions, or metrics are disclosed in the provided filing information. No positive or negative metrics are mentioned.

26-02-2026

Manhattan Associates Inc filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

26-02-2026

URBAN OUTFITTERS INC filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-074606, size 1 MB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. This is a multi-item filing with no quantitative data, positive or negative metrics, or directional implications mentioned.

26-02-2026

Organogenesis Holdings Inc. filed a Form 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), disclosing financial results. This multi-item filing appears timely based on the filing date matching the event date. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics were explicitly stated in the provided filing information.

26-02-2026

International Bancshares Corp filed an 8-K on February 26, 2026 (AccNo: 0001104659-26-020307, Size: 170 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons are disclosed in the provided filing summary. This is an informational earnings-related disclosure with no quantitative details available.

26-02-2026

FS Bancorp, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, financial statements, or exhibits are disclosed. No quantitative metrics, comparisons, or directional impacts are provided.

26-02-2026

UNION BANKSHARES INC filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative data are disclosed in the provided filing information.

26-02-2026

MP Materials Corp. filed an 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing summary. This appears to be a standard earnings-related disclosure without detailed financial data available.

26-02-2026

Xenon Pharmaceuticals Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-076530), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure typical for financial results announcements, but no specific revenue, earnings, guidance, or quantitative metrics are disclosed in the provided filing information. No positive or negative performance indicators, period-over-period changes, or balance sheet details are available.

26-02-2026

Syndax Pharmaceuticals Inc filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-076522), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet impacts, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with exhibits likely containing detailed financials.

26-02-2026

Neurogene Inc. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing with no specific financial metrics, transactions, or operational details disclosed in the provided filing information. Critical content of the disclosure is NOT_DISCLOSED.

26-02-2026

Biodesix Inc filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-076521), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits provided under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative financial data were disclosed in the provided filing details. This is a standard voluntary disclosure of financial results with no directional performance indicators available.

• ·Filing size: 559 KB
• ·Sector: NOT_DISCLOSED

26-02-2026

Strategic Storage Trust VI, Inc. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details, financial metrics, transactions, or directional information are disclosed in the filing summary.

26-02-2026

DENTSPLY SIRONA Inc. filed a Form 8-K on 2026-02-26 reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, revenue figures, earnings, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a standard disclosure for financial results without quantified details.

26-02-2026

Unity Bancorp Inc./NJ/ filed a Form 8-K on February 26, 2026 (AccNo: 0000920427-26-000008, Size: 226 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, financial statements, or exhibits are disclosed in the provided filing information. All quantitative metrics, transactions, and impacts are NOT_DISCLOSED.

26-02-2026

Alpha Teknova, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-076592), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item filing focused on financial results, but no specific revenue, earnings, balance sheet details, period-over-period changes, guidance, or other quantitative metrics are mentioned in the provided filing information. No positive or negative performance indicators are available.

26-02-2026

Phillips Edison & Company, Inc. filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, which are mandatory disclosures. Item 8.01 covers other events and Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, financial impacts, or performance metrics (positive, negative, or flat) are disclosed.

• ·Multi-item 8-K filing (Items 1.01, 2.03, 8.01, 9.01)
• ·Filed same day as event date (2026-02-26), indicating timely disclosure

26-02-2026

Definitive Healthcare Corp. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits (AccNo: 0001193125-26-076609, Size: 1 MB). No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. Sector is not specified.

26-02-2026

Dell Technologies Inc. filed an 8-K on February 26, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no detailed performance data available.

26-02-2026

Emergent BioSolutions Inc. filed an 8-K on 2026-02-26 disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item filing pertains to financial results but provides no specific revenue, earnings, or other quantitative metrics. No positive or negative performance indicators, guidance, or period-over-period comparisons are detailed in the available information.

26-02-2026

Strategic Education, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 announcing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons were disclosed in the filing information provided. This represents a standard voluntary earnings-related disclosure without quantifiable performance metrics.

26-02-2026

Denali Therapeutics Inc. filed an 8-K on February 26, 2026 (AccNo: 0001714899-26-000020), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This constitutes a multi-item voluntary disclosure of financial results with no specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons provided in the filing description. No positive or negative metrics are disclosed.

26-02-2026

Clover Health Investments, Corp. /DE filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are detailed in the provided filing information. This represents a standard mandatory disclosure for financial results without quantified impacts.

26-02-2026

Global Net Lease, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001104659-26-020505, size: 304 KB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transactions, operational data, or other details are explicitly stated in the filing summary provided. This is a multi-item filing likely involving voluntary disclosure of material information with attached exhibits.

26-02-2026

Flutter Entertainment plc filed an 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This represents a standard voluntary earnings-related disclosure with no detailed performance data available.

26-02-2026

Crinetics Pharmaceuticals, Inc. filed a Form 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. This is a standard voluntary earnings-related disclosure with AccNo 0001658247-26-000011 and file size 295 KB. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance are disclosed in the provided filing information.

• ·AccNo: 0001658247-26-000011
• ·File Size: 295 KB
• ·Sector: NOT_DISCLOSED

26-02-2026

Dexcom Inc filed an 8-K on February 26, 2026 (AccNo: 0001093557-26-000031), disclosing under Item 5.02 a departure of directors or certain officers, election or appointment of directors or officers, and/or compensatory arrangements of certain officers. The filing also includes Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. No specific details on positions affected, individuals involved, reasons for changes, timing, or quantitative impacts are disclosed.

26-02-2026

AFFILIATED MANAGERS GROUP, INC. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer, position affected, reasons, or any quantitative metrics are disclosed.

26-02-2026

Village Farms International, Inc. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific core event, financial metrics, transactions, or quantitative data are detailed in the provided filing information. This appears to be a multi-item informational filing with attached exhibits, likely a press release or presentation.

26-02-2026

Amphastar Pharmaceuticals, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001297184-26-000007), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, margins, guidance, period-over-period comparisons, or other financial metrics were provided in the filing details. This appears to be a standard earnings-related disclosure without quantified performance data.

26-02-2026

Monster Beverage Corp filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided information. This is a standard earnings-related multi-item filing with no details on positive or negative performance.

26-02-2026

Ambarella Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02 and an officer change or election/appointment under Item 5.02, with exhibits under Item 9.01. Specific details on the affected officer position, whether it is an appointment or departure, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the filing summary.

26-02-2026

Isabella Bank Corp filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing summary. This is a multi-item informational filing with no quantitative data or performance metrics mentioned.

26-02-2026

Rocket Pharmaceuticals, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001140361-26-006981), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet effects, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a standard financial results disclosure without quantified metrics available.

26-02-2026

Baldwin Insurance Group, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001781755-26-000015), disclosing Results of Operations and Financial Condition under Item 2.02 along with Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are mentioned in the provided filing details. This is a standard financial results announcement with no quantitative metrics or directional performance indicators available.

26-02-2026

SBA Communications Corp filed a Form 8-K on 2026-02-26 reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing furnishing financial results with attached exhibits (AccNo: 0001193125-26-076767, Size: 609 KB). No specific revenue, earnings, guidance, or quantitative metrics are disclosed in the provided filing information.

26-02-2026

Abbott Laboratories filed an 8-K on 2026-02-26 reporting Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction value, financial impacts, or metrics are disclosed. This is a mandatory disclosure of a material event without quantified positive or negative elements.

26-02-2026

Federal Signal Corp (/DE/) disclosed an officer change event via 8-K filing on 2026-02-26 under Item 5.02, covering departures of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative impacts are provided.

26-02-2026

BROADWAY FINANCIAL CORP DE filed an 8-K on February 26, 2026, under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events, transactions, financial metrics, or exhibits are disclosed in the filing summary. No quantitative data, comparisons, or directional impacts provided.

26-02-2026

RED RIVER BANCSHARES INC filed a Form 8-K on February 26, 2026, under Item 5.03 disclosing amendments to its Articles of Incorporation or Bylaws or a change in fiscal year, with Item 9.01 listing financial statements and exhibits. No specific details on the nature of the amendments, dollar values, strategic rationale, or financial impacts are provided. This is a multi-item mandatory filing with no quantitative metrics or period-over-period comparisons disclosed.

26-02-2026

TTEC Holdings, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. This is a multi-item filing typical for earnings announcements. No specific revenue, earnings, guidance, or period-over-period metrics were detailed in the provided filing information.

26-02-2026

Avery Dennison Corp filed an 8-K on February 26, 2026, reporting under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 discloses financial statements and exhibits. No quantitative financial metrics, transaction values, or specific details on the amendments are provided.

26-02-2026

Eagle Bancorp Montana, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative data such as compensation amounts are disclosed. Filing size is 154 KB with AccNo 0001437749-26-005899.

• ·AccNo: 0001437749-26-005899
• ·Sector: NOT_DISCLOSED

26-02-2026

STONERIDGE INC filed a Form 8-K on 2026-02-26 reporting multiple items: Item 1.01 Entry into a Material Definitive Agreement, Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, personnel changes, disclosures, dollar values, financial impacts, or quantitative metrics are disclosed in the provided filing summary. This is a multi-item filing with no period-over-period comparisons, guidance, or scheduled events mentioned.

26-02-2026

NewMarket Corp filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-077261, Size: 143 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, transactions, financial metrics, or exhibits are disclosed in the provided filing summary. This appears to be an informational filing with no quantified positive or negative impacts mentioned.

26-02-2026

Civista Bancshares, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on positions affected, names, reasons, timing, or any quantitative metrics are disclosed.

26-02-2026

Metropolitan Bank Holding Corp. filed a multi-item Form 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 a Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction terms, financial impacts, or disclosures are provided in the available metadata. This is an informational filing with no quantified metrics or period-over-period comparisons disclosed.

26-02-2026

Legato Merger Corp. III filed an 8-K on 2026-02-26 disclosing entry into a Material Definitive Agreement under Item 1.01, likely related to a merger/acquisition, along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific deal structure, parties, valuation, synergies, or financial metrics are disclosed in the provided filing summary. This informational filing signals a significant transaction but lacks details for full assessment.

• ·Filing Accession Number: 0001829126-26-001675
• ·File Size: 919 KB

26-02-2026

Technology & Telecommunication Acquisition Corp filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger or acquisition. The filing also covers amendments to articles of incorporation or bylaws and potential change in fiscal year under Item 5.03, as well as submission of matters to a vote of security holders under Item 5.07, with financial statements and exhibits under Item 9.01. No specific transaction parties, terms, valuations, synergies, or financial metrics are disclosed.

26-02-2026

Propanc Biopharma, Inc. filed an 8-K on 2026-02-26 disclosing an officer or director change under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, names, appointment or resignation status, reasons, timing, or compensation are disclosed.

26-02-2026

NKGen Biotech, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 discloses financial statements and exhibits, likely including the agreement. No quantitative details, financial impacts, positive or negative metrics, or further context on the transaction are provided.